Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

BACKGROUND: Cemiplimab, a high-affinity, potent human immunoglobulin G4 monoclonal antibody to programmed cell death-1 demonstrated antitumor activity in a Phase 1 advanced cutaneous squamous cell carcinoma (CSCC) expansion cohort (NCT02383212) and the pivotal Phase 2 study (NCT02760498). Here we re...

Descripción completa

Detalles Bibliográficos
Autores principales: Rischin, Danny, Migden, Michael R, Lim, Annette M, Schmults, Chrysalyne D, Khushalani, Nikhil I, Hughes, Brett G M, Schadendorf, Dirk, Dunn, Lara A, Hernandez-Aya, Leonel, Chang, Anne Lynn S, Modi, Badri, Hauschild, Axel, Ulrich, Claas, Eigentler, Thomas, Stein, Brian, Pavlick, Anna C, Geiger, Jessica L, Gutzmer, Ralf, Alam, Murad, Okoye, Emmanuel, Mathias, Melissa, Jankovic, Vladimir, Stankevich, Elizabeth, Booth, Jocelyn, Li, Siyu, Lowy, Israel, Fury, Matthew G, Guminski, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304829/
https://www.ncbi.nlm.nih.gov/pubmed/32554615
http://dx.doi.org/10.1136/jitc-2020-000775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304829/
https://www.ncbi.nlm.nih.gov/pubmed/32554615
http://dx.doi.org/10.1136/jitc-2020-000775

Ejemplares similares